Interim results from an ongoing phase I study in HPV-16-positive recurrent/metastatic HNSCC demonstrated an ORR of 47% and median PFS of 5.8 months for the combination of CUE-101 and pembrolizumab among 19 evaluable PD-L1-positive patients in the first-line setting. Here, CD274 is linked to head and neck squamous cell carcinoma.